跳至主要内容
临床试验/NCT05172453
NCT05172453招募中不适用

A Real World, Multi-center Study on Mother-to-child Transmission of Hepatitis B Virus in China

Nanfang Hospital, Southern Medical University15 个研究点 分布在 1 个国家目标入组 50,000 人开始时间: 2015年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
50,000
试验地点
15
主要终点
rate of birth defect

研究概览

简要总结

In order to evaluate the feasibility of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030, a multi-center, prospective cohorts study was conducted to investigate MTCT of HBV in China.

详细描述

A prospective, multicenter study of pregnant women with HBV infection was conducted from July 2015 up to now in a real world setting in the Shield Project stage Ⅱ. Inclusion criteria was any pregnant women with chronic HBV infection. Pregnant women were excluded if they had a positive serologic test for human immunodeficiency virus or hepatitis C virus or any co-morbidity that might reduce compliance or if they were unable or unwilling to use the mobile health application-Shield APP. Enrolled mothers and infants were prospectively followed until infant post-vaccination serologic testing (PVST) was performed at 7-12 months of age.

Demographic data, antiviral treatment history, pregnancy and labour history, co-morbidity, HBV serologic marker tests, HBV DNA tests, liver function tests, mode of delivery, neonatal characteristics (height, weight, head circumference, Apgar score and any major birth defect), breastfeeding and PVST for infants at 7-12 months of age were collected.

A mobile health application called "SHIELD" was developed and used in the Shield Project stage Ⅱ to collect data and provide support for communication between mothers and their doctors. All laboratory test reports, questionnaires and other relevant information was uploaded into SHIELD. Participants could consult with their doctors via SHIELD during the follow-up.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • pregnant women with chronic HBV infection.

排除标准

  • positive serologic test for human immunodeficiency virus or hepatitis C virus;
  • any co-morbidity that might reduce compliance;
  • unable or unwilling to use the mobile health application-Shield APP

结局指标

主要结局

rate of birth defect

时间窗: 5 years

compare rate of birth defect among children born to mothers with and without antiviral therapy during pregnancy

rate of mother-to-child transmission of HBV

时间窗: 5 years

compare rate of mother-to-child transmission of HBV among children born to mothers with and without antiviral therapy during pregnancy

次要结局

  • change of HBV DNA level in mothers with antiviral therapy from baseline to withdrawal of antiviral drugs(from enrollment to delivery, assessed up to 40 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jinlin Hou

Professor & Director

Nanfang Hospital, Southern Medical University

研究点 (15)

Loading locations...

相似试验